Inovio Biomedical Corporation Named “Best Early Stage Biotech” Company at World Vaccine Congress 2010

BLUE BELL, Pa.--(BUSINESS WIRE)--Inovio Biomedical Corporation (NYSE Amex: INO), a leader in DNA vaccine design, development and delivery, announced today that the company was awarded a Vaccine Industry Excellence Award in the category of “Best Early Stage Biotech” by a panel of judges composed of a broad selection of biotech industry stakeholders. The award was presented at the World Vaccine Congress being held April 19 - 22, 2010, in Washington, D.C.

MORE ON THIS TOPIC